Physicians would have to register with the Drug Enforcement Administration (DEA) for telehealth prescribing of certain controlled substances under a proposed rule issued Wednesday by the agency.

“The proposed registration requirements for telemedicine-based prescribing and dispensing create a new business activity within DEA’s overarching registration framework, distinguishing it from ...

On January 16, the U.S. Drug Enforcement Administration (DEA) announced three new telemedicine rules that extend prescribing flexibilities ...

The Drug Enforcement Administration ("DEA") announced three new regulations related to the prescription of controlled substances resulting from ...

On Wednesday, the DEA released a proposed rule that would set up a special registration process for remote prescribing of Schedule II-V controlled substances such as Xanax, Vicodin and Adderall.

The move finally fulfills a mandate that DEA had largely ignored since Congress first issued it in 2008. But the new special registration system is merely a proposal, meaning the incoming Trump ad ...

“The proposed registration requirements for telemedicine-based prescribing and dispensing create a new business activity within DEA’s overarching registration framework, distinguishing it from ...

The DEA also released a final rule on Wednesday for its 2023 proposal that sets up a special registration process for remote prescribing of buprenorphine, a medication used to treat opioid use ...

Congress first directed the DEA to create the special registration program in 2008. That law prevented providers from prescribing controlled substances through telehealth unless they received such ...

Interest groups responded cautiously to the rules' release. "While we are still digesting the DEA's Special Registration framework ... it is clear that these updates carry significant implications ...